OncoPharm Updates from December 2020
Jan 7, 2021
This discussion unveils five significant FDA updates from December 2020, emphasizing pralcetinib's new role in RET-mutated medullary thyroid cancer. Delve into the clinical promise of HER2-targeting margituximab for breast cancer. Explore the safety of relugolix in hormone-sensitive prostate cancer treatments and recent advancements in selenexor and its Boston study. The intricate pharmacokinetics of new drugs also sheds light on tailored dosage strategies in oncology pharmacy.
AI Snips
Chapters
Transcript
Episode notes
Host's Post-Vaccine Update
- John Bazar mentions he is nine days post-Pfizer vaccine and feeling good.
- He uses this personal update to open the episode before discussing FDA updates.
Pralsetinib Is An Expanded RET Indication
- Pralsetinib is an expanded RET inhibitor approval now for RET-mutated medullary thyroid cancer, not a new chemical entity.
- It also inhibits VEGF, which explains hypertension, impaired wound healing, and hemorrhage risks.
Margatuximab Shows Modest Benefit
- Margatuximab showed only a modest PFS benefit over trastuzumab plus chemo in heavily pretreated HER2+ breast cancer.
- The control arm lacked dual HER2 blockade, limiting how practice-changing the result can be.